Environmental and Genetic Factors Associated with Morphine Response in the Postoperative Period
Overview
Authors
Affiliations
Objective: The aim of this study was to investigate the respective influence of genetic and nongenetic factors on morphine dose requirements and adverse effects after colorectal surgery.
Methods: Seventy-four patients who planned to undergo colorectal surgery were included in this pilot study. The cumulative 24-hour postoperative dose of morphine and postoperative nausea or vomiting requiring the antiemetic ondansetron were the 2 clinical end points. The association of patient characteristics, A118G mu-opioid receptor (OPRM1) single-nucleotide polymorphism (SNP); T802C uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7) SNP; and 2 adenosine triphosphate-binding cassette, subfamily B, member 1 (ABCB1) (multidrug resistance 1 [MDR1]) exonic SNPs (G2677T/A and C3435T) with study end points was investigated.
Results: Age, creatinine clearance, and the regular use of psychotropic agents were found to be significantly associated with postoperative morphine dose requirements by univariate analysis. Multivariate analysis identified that age (P = .01) and the use of psychotropic agents before surgery (P = .03) were positively associated with a higher rate of morphine consumption. A higher weight (P = .05) and the ABCB1 homozygous GG-CC diplotype (P = .03) were significantly associated with fewer morphine side effects by univariate analysis. The homozygous ABCB1 diplotype (GG-CC) conferred an odds ratio of 0.12 (95% confidence interval, 0.01-0.98) with regard to the use of ondansetron for postoperative nausea or vomiting. Multivariate analysis identified that the ABCB1 GG-CC diplotype was the only borderline-significant (P = .07) predictive factor of morphine side effects.
Conclusion: Age and prior use of psychotropic agents are associated with postoperative morphine dose requirements. Whether ABCB1 polymorphisms might predict morphine side effects remains to be determined.
Olleik G, Lapointe-Gagner M, Jain S, Shirzadi S, Nguyen-Powanda P, Al Ben Ali S Surg Endosc. 2024; 39(1):492-503.
PMID: 39400599 DOI: 10.1007/s00464-024-11322-8.
Personalized Approaches to Spine Surgery.
Patel A, Dada A, Saggi S, Yamada H, Ambati V, Goldstein E Int J Spine Surg. 2024; .
PMID: 39191475 PMC: 11687043. DOI: 10.14444/8644.
Lewandrowski K, Sharafshah A, Elfar J, Schmidt S, Blum K, Wetzel F Cell Mol Neurobiol. 2024; 44(1):47.
PMID: 38801645 PMC: 11129978. DOI: 10.1007/s10571-024-01466-5.
Pharmacogenetic Approaches in Personalized Medicine for Postoperative Pain Management.
Ferreira do Couto M, Fonseca S, Pozza D Biomedicines. 2024; 12(4).
PMID: 38672085 PMC: 11048650. DOI: 10.3390/biomedicines12040729.
Lilic J, Marjanovic V, Budic I, Stefanovic N, Stokanovic D, Marjanovic G Pharmgenomics Pers Med. 2024; 17:41-49.
PMID: 38313794 PMC: 10838050. DOI: 10.2147/PGPM.S443035.